Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-CIRCUIT: Uninterrupted dabigatran etexilate vs warfarin during pulmonary vein ablation
2014-003890-40Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dabigatran in Atrial fibrillation (AFib) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of major bleeding events. Started Jan 2015; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2014-003890-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003890-40.